Elixir Medical's DynamX System Receives FDA Breakthrough Designation for Ischemic Heart Disease

The DynamX® Sirolimus-Eluting Coronary Bioadaptor System by Elixir Medical marks a significant advancement in cardiovascular disease treatment. 

This bioadaptive implant, granted Breakthrough Device Designation by the FDA, features an innovative design that enhances outcomes for patients with symptomatic ischemic heart disease due to specific native coronary artery lesions. 

The bioadaptor operates through three phases: initially, it establishes maximum blood flow and restores hemodynamic function to alleviate coronary artery disease symptoms. 

In the second phase, as tissue encapsulates the bioadaptor and the absorbable polymer coating is resorbed, its helical strands unlock and separate, allowing the vessel to grow and adapt while maintaining the blood flow lumen. 

In the final dynamic support phase, the separated strands provide ongoing support, restoring vessel viability by reinstating pulsatility, compliance, adaptive blood flow volume, and promoting plaque stabilization and regression. 

Recent clinical trials, shown significant benefits over standard treatments, including a notable reduction in Target Lesion Failure rates in critical coronary artery segments. 

The limitations of traditional drug-eluting stents and bioresorbable scaffolds, the device reduces adverse events and maintains long-term vessel health. 

The Company aiming to elevate the standard of care in cardiovascular disease treatment. 

The DynamX bioadaptor represents a pioneering approach in coronary implant technology, designed to restore and maintain vessel health through its unique mechanism of action, potentially setting a new standard in cardiovascular disease management.

Source: https://elixirmedical.com/elixir-medicals-dynamx-sirolimus-eluting-coronary-bioadaptor-system-granted-fda-breakthrough-device-designation-for-the-treatment-of-symptomatic-ischemic-heart-disease/